New York State Common Retirement Fund Buys 69,257 Shares of Guardant Health, Inc. (NASDAQ:GH)

New York State Common Retirement Fund increased its stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 184.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 106,884 shares of the company's stock after buying an additional 69,257 shares during the period. New York State Common Retirement Fund owned about 0.09% of Guardant Health worth $4,553,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new position in shares of Guardant Health during the fourth quarter valued at approximately $2,211,000. Commonwealth Equity Services LLC acquired a new stake in shares of Guardant Health during the 4th quarter worth $293,000. Cibc World Markets Corp acquired a new stake in shares of Guardant Health during the 4th quarter worth $346,000. Xponance Inc. acquired a new position in Guardant Health in the fourth quarter valued at $261,000. Finally, Summit Global Investments purchased a new stake in Guardant Health during the fourth quarter valued at about $630,000. Hedge funds and other institutional investors own 92.60% of the company's stock.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, Director Myrtle S. Potter sold 2,626 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $49.70, for a total transaction of $130,512.20. Following the transaction, the director owned 18,180 shares in the company, valued at $903,546. This trade represents a 12.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Meghan V. Joyce sold 3,337 shares of the firm's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $47.22, for a total value of $157,573.14. Following the completion of the transaction, the director owned 11,150 shares in the company, valued at $526,503. The trade was a 23.03% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 342,300 shares of company stock worth $17,082,238. 6.10% of the stock is currently owned by corporate insiders.

Guardant Health Stock Down 0.6%

Shares of GH traded down $0.29 on Thursday, hitting $45.16. The company's stock had a trading volume of 579,975 shares, compared to its average volume of 2,260,369. The firm's fifty day moving average price is $46.58 and its 200-day moving average price is $44.57. Guardant Health, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $53.42. The firm has a market capitalization of $5.59 billion, a price-to-earnings ratio of -13.32 and a beta of 1.44.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.08. The company had revenue of $203.47 million during the quarter, compared to analyst estimates of $189.91 million. The company's quarterly revenue was up 20.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.46) EPS. As a group, equities analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GH has been the subject of several recent research reports. Stephens reissued an "overweight" rating and issued a $55.00 price objective on shares of Guardant Health in a research report on Wednesday, March 26th. Barclays increased their price objective on shares of Guardant Health from $55.00 to $60.00 and gave the stock an "overweight" rating in a report on Thursday, May 1st. Canaccord Genuity Group boosted their price target on shares of Guardant Health from $60.00 to $65.00 and gave the company a "buy" rating in a report on Thursday, May 1st. Mizuho raised their price target on shares of Guardant Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a report on Friday, June 13th. Finally, TD Securities lifted their price target on shares of Guardant Health from $56.00 to $60.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. Twenty research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $54.45.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.